146 related articles for article (PubMed ID: 8319997)
1. Comparative effects of three different potent renin inhibitors in primates.
Clozel JP; Fischli W
Hypertension; 1993 Jul; 22(1):9-17. PubMed ID: 8319997
[TBL] [Abstract][Full Text] [Related]
2. Ro 42-5892 is a potent orally active renin inhibitor in primates.
Fischli W; Clozel JP; el Amrani K; Wostl W; Neidhart W; Stadler H; Branca Q
Hypertension; 1991 Jul; 18(1):22-31. PubMed ID: 1830563
[TBL] [Abstract][Full Text] [Related]
3. Effects of the blockade of the renin-angiotensin system in cyclosporin-induced hypertension.
Clozel JP; Fischli W; Ménard J
J Hypertens; 1993 Jan; 11(1):75-81. PubMed ID: 8382242
[TBL] [Abstract][Full Text] [Related]
4. Hemodynamic and biochemical consequences of renin inhibition by infusion of CGP 38560A in normal volunteers.
Nussberger J; Delabays A; De Gasparo M; Cumin F; Waeber B; Brunner HR; Ménard J
Hypertension; 1989 Jun; 13(6 Pt 2):948-53. PubMed ID: 2661435
[TBL] [Abstract][Full Text] [Related]
5. Effects of renin-angiotensin system blockade in guinea pigs.
Véniant M; Clozel JP; Hess P; Fischli W
Hypertension; 1992 Mar; 19(3):255-62. PubMed ID: 1532164
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics and efficacy of renin inhibitors.
Rongen GA; Lenders JW; Smits P; Thien T
Clin Pharmacokinet; 1995 Jul; 29(1):6-14. PubMed ID: 7586899
[TBL] [Abstract][Full Text] [Related]
7. Discovery of remikiren as the first orally active renin inhibitor.
Clozel JP; Fischli W
Arzneimittelforschung; 1993 Feb; 43(2A):260-2. PubMed ID: 8498974
[TBL] [Abstract][Full Text] [Related]
8. Ciprokiren (Ro 44-9375). A renin inhibitor with increasing effects on chronic treatment.
Fischli W; Clozel JP; Breu V; Buchmann S; Mathews S; Stadler H; Vieira E; Wostl W
Hypertension; 1994 Aug; 24(2):163-9. PubMed ID: 8039839
[TBL] [Abstract][Full Text] [Related]
9. Renin inhibitors in hypertension.
Luther RR; Glassman HN; Boger RS
Clin Nephrol; 1991 Oct; 36(4):181-6. PubMed ID: 1959244
[TBL] [Abstract][Full Text] [Related]
10. Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension.
Azizi M; Guyene TT; Chatellier G; Ménard J
J Hypertens; 1994 Apr; 12(4):419-27. PubMed ID: 8064166
[TBL] [Abstract][Full Text] [Related]
11. Effects of chronic infusion of renin inhibitor A-64662 in sodium-depleted monkeys.
Verburg KM; Kleinert HD; Kadam JR; Chekal MA; Mento PF; Wilkes BM
Hypertension; 1989 Mar; 13(3):262-72. PubMed ID: 2646217
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological properties of YM-21095, a potent and highly specific renin inhibitor.
Shibasaki M; Asano M; Fukunaga Y; Usui T; Ichihara M; Murakami Y; Nakano K; Fujikura T
Am J Hypertens; 1991 Dec; 4(12 Pt 1):932-8. PubMed ID: 1815649
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the role of the renin-angiotensin system in cardiac contractility utilizing the renin inhibitor remikiren.
van Kats JP; Sassen LM; Danser AH; Polak MP; Soei LK; Derkx FH; Schalekamp MA; Verdouw PD
Br J Pharmacol; 1996 Mar; 117(5):891-901. PubMed ID: 8851507
[TBL] [Abstract][Full Text] [Related]
14. Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans.
Delabays A; Nussberger J; Porchet M; Waeber B; Hoyos P; Boger R; Glassman H; Kleinert HD; Luther R; Brunner HR
Hypertension; 1989 Jun; 13(6 Pt 2):941-7. PubMed ID: 2661434
[TBL] [Abstract][Full Text] [Related]
15. Remikiren (Ro 42-5892)--an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system.
Himmelmann A; Bergbrant A; Svensson A; Hansson L; Aurell M
Am J Hypertens; 1996 Jun; 9(6):517-22. PubMed ID: 8783774
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin converting enzyme inhibition and renin inhibition.
Nussberger J; Waeber B; Brunner HR
J Hypertens Suppl; 1989 Apr; 7(2):S75-9. PubMed ID: 2666618
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects.
Kleinbloesem CH; Weber C; Fahrner E; Dellenbach M; Welker H; Schröter V; Belz GG
Clin Pharmacol Ther; 1993 May; 53(5):585-92. PubMed ID: 8491068
[TBL] [Abstract][Full Text] [Related]
18. Renal and systemic effects of the renin inhibitor remikiren in patients with essential hypertension.
van Paassen P; de Zeeuw D; de Jong PE
J Cardiovasc Pharmacol; 1995 Jul; 26(1):39-45. PubMed ID: 7564363
[TBL] [Abstract][Full Text] [Related]
19. Expression of components of the RAS during prolonged blockade at different levels in primates.
Samani NJ; Cumin F; Kelly M; Wood JM
Am J Physiol; 1994 Oct; 267(4 Pt 1):E612-9. PubMed ID: 7943312
[TBL] [Abstract][Full Text] [Related]
20. Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat.
Neutel JM; Luther RR; Boger RS; Weber MA
Am Heart J; 1991 Oct; 122(4 Pt 1):1094-100. PubMed ID: 1656720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
